Amendments To The Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

What is claimed is:

1. (Currently Amended) A compound of Formula I:

$$R^{1}$$
 $(R^{2})_{n}$
 R^{3}
 (I)

including <u>pharmaceutically acceptable</u> salts, <u>solvates</u>, <u>and pharmaceutically</u> acceptable derivatives thereof wherein

R¹ is -CH=CH-R⁵;

R⁵ is selected from -CN, -C(O)OH, and -C(O)-N(R⁶)(R⁷);

R⁶ and R⁷ each independently are <u>selected from</u> hydrogen [[,]] <u>and</u> <u>unsubstituted</u> alkyl, aryl; or

R⁶ and R⁷ may combine with the nitrogen atom to which they are attached to form a <u>piperidinyl</u> 3 to 7 membered ring, where said ring may be optionally substituted:

each R² independently is <u>selected from</u> hydrogen, halogen, halogen, haloalkyl, hydroxy, <u>and</u> alkoxy, aryloxy, aralkyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, aralkyloxycarbonyloxy, aralkylsulfonyloxy, arylsulfonyloxy, aralkylsulfonyloxy, or acyloxy;

n is 1 or 2;

R³ is <u>selected from</u> hydrogen, hydroxy, <u>unsubstituted</u> alkyl, alkoxy, <u>phenyl,</u> aryloxy, aralkyloxy, haloalkylsulfonyloxy, halogen, <u>and</u> haloalkyl, aryl, heteroaryl, aralkyl, or heteroaralkyl;

X is -O-, -S-, -S(O)-, or -S(O)₂-;

each R⁴ independently is <u>selected from</u> hydrogen, halogen, halogen, and grant halogen, ha

m is 1 or 2.

- 2. (Canceled).
- 3. (Canceled).
- 4. (Original) The compound of claim 1 wherein X is O or S.
- 5. (Original) The compound of claim 4 wherein X is O.
- 6. (Currently Amended) The compound of claim 1 wherein n is 1 and R² is selected from hydroxyl, and alkoxy, or aralkyloxy.
- 7. (Original) The compound of claim 6 wherein R² is hydroxy substituted on the 7 position of the depicted quinoline ring.
- 8. (Currently Amended) The compound of claim 1 wherein R³ is <u>selected</u> from alkyl, hydroxyl, aralkyloxy, haloalkylsulfonyloxy, or aryl, and phenyl.
- 9. (Original) The compound of claim 8 wherein R^3 is C_1 - C_6 alkyl or phenyl.
- 10. (Original) The compound of claim 9 wherein R³ is ethyl.
- 11. (Original) The compound of claim 1 wherein m is 1 and R⁴ is hydrogen.
- 12. (Original) The compound of claim 1 wherein m is 1 and R⁴ is haloalkyl.
- 13. (Original) The compound of claim 12 wherein R⁴ is –CF₃ and is substituted in the 3 position on the depicted phenyl ring.
- 14. (Previously Presented) A compound selected from the group consisting of:
- 4-[(7-Hydroxy-2-ethyl-3-phenyl-4-quinolinyl)oxyphenyl]-2-propenoic acid;
- 4-[(7-Hydroxy-2-ethyl-3-phenyl-4-quinolinyl)oxyphenyl]-2-propenoamide;

- 4-[(7-Hydroxy-2-ethyl-3-phenyl-4-quinolinyl)oxyphenyl]-2-propeno-N-isopropylamide;
- 4-[(7-Hydroxy-2-ethyl-3-phenyl-4-quinolinyl)oxyphenyl]-2-propeno-N,N-dimethylamide;
- 4-[(7-Hydroxy-2-ethyl-3-phenyl-4-quinolinyl)oxyphenyl]-2-propeno-N-piperidineamide;
- 4-[(7-Hydroxy-2-ethyl-3-phenyl-4-quinolinyl)oxyphenyl]-2-propenonitrile;
- 4-[(7-Hydroxy-2-ethyl-3-(3-trifluoromethylphenyl)-4-quinolinyl)oxyphenyl]-2-propeno-N-isopropylamide;
- 4-[(7-Hydroxy-2-ethyl-3-(3-trifluoromethylphenyl)-4-quinolinyl)oxyphenyl]-2-propenoic acid;
- 4-[(7-Hydroxy-2-phenyl-3-phenyl-4-quinolinyl)oxyphenyl]-2-propenoic acid;
- 3-[(7-Hydroxy-2-ethyl-3-phenyl-4-quinolinyl)oxyphenyl]-2-propenoic acid; and
- 4-[(7-Hydroxy-2-ethyl-3-phenyl-4-quinolinyl)thiophenyl]-2-propenoamide.
- 15. (Canceled).
- 16. (Previously Presented) A pharmaceutical composition comprising a compound according to claim 1.
- 17. (Original) The pharmaceutical composition of claim 16 further comprising a pharmaceutically acceptable excipient, carrier, diluent, or mixtures thereof.
- 18. (Canceled).
- 19. (Canceled).
- 20. (Canceled).
- 21. (Canceled).
- 22. (Canceled).
- 23. (Canceled).
- 24. (Canceled).
- 25. (Canceled).

- 26. (Canceled).
- 27. (Canceled).